123 related articles for article (PubMed ID: 14763161)
1. The mitogen-activated protein kinase signaling module as a therapeutic target in hematologic malignancies.
Milella M; Kornblau SM; Andreeff M
Rev Clin Exp Hematol; 2003 Jun; 7(2):160-90. PubMed ID: 14763161
[TBL] [Abstract][Full Text] [Related]
2. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
3. Indomethacin induces apoptosis in 786-O renal cell carcinoma cells by activating mitogen-activated protein kinases and AKT.
Ou YC; Yang CR; Cheng CL; Raung SL; Hung YY; Chen CJ
Eur J Pharmacol; 2007 Jun; 563(1-3):49-60. PubMed ID: 17341418
[TBL] [Abstract][Full Text] [Related]
4. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
5. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.
Friday BB; Adjei AA
Clin Cancer Res; 2008 Jan; 14(2):342-6. PubMed ID: 18223206
[TBL] [Abstract][Full Text] [Related]
6. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.
Yang R; Piperdi S; Gorlick R
Clin Cancer Res; 2008 Oct; 14(20):6396-404. PubMed ID: 18927278
[TBL] [Abstract][Full Text] [Related]
7. Development and implementation of three mitogen-activated protein kinase (MAPK) signaling pathway imaging assays to provide MAPK module selectivity profiling for kinase inhibitors: MK2-EGFP translocation, c-Jun, and ERK activation.
Nickischer D; Laethem C; Trask OJ; Williams RG; Kandasamy R; Johnston PA; Johnston PA
Methods Enzymol; 2006; 414():389-418. PubMed ID: 17110204
[TBL] [Abstract][Full Text] [Related]
8. Raf: a strategic target for therapeutic development against cancer.
Beeram M; Patnaik A; Rowinsky EK
J Clin Oncol; 2005 Sep; 23(27):6771-90. PubMed ID: 16170185
[TBL] [Abstract][Full Text] [Related]
9. p38 MAP kinase: a convergence point in cancer therapy.
Olson JM; Hallahan AR
Trends Mol Med; 2004 Mar; 10(3):125-9. PubMed ID: 15102355
[TBL] [Abstract][Full Text] [Related]
10. Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation.
Yu C; Friday BB; Lai JP; McCollum A; Atadja P; Roberts LR; Adjei AA
Clin Cancer Res; 2007 Feb; 13(4):1140-8. PubMed ID: 17317822
[TBL] [Abstract][Full Text] [Related]
11. Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer.
Shi YY; Small GW; Orlowski RZ
Breast Cancer Res Treat; 2006 Nov; 100(1):33-47. PubMed ID: 16807678
[TBL] [Abstract][Full Text] [Related]
12. The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors.
Alvarez RH; Kantarjian HM; Cortes JE
Cancer; 2006 Oct; 107(8):1918-29. PubMed ID: 16986126
[TBL] [Abstract][Full Text] [Related]
13. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
Roberts PJ; Der CJ
Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
[TBL] [Abstract][Full Text] [Related]
14. Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies.
Chalandon Y; Schwaller J
Haematologica; 2005 Jul; 90(7):949-68. PubMed ID: 15996933
[TBL] [Abstract][Full Text] [Related]
15. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
16. Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses.
Giafis N; Katsoulidis E; Sassano A; Tallman MS; Higgins LS; Nebreda AR; Davis RJ; Platanias LC
Cancer Res; 2006 Jul; 66(13):6763-71. PubMed ID: 16818652
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of peripheral benzodiazepine receptor ligand-induced apoptosis and cell cycle arrest of esophageal cancer cells by simultaneous inhibition of MAPK/ERK kinase.
Sutter AP; Maaser K; Gerst B; Krahn A; Zeitz M; Scherübl H
Biochem Pharmacol; 2004 May; 67(9):1701-10. PubMed ID: 15081869
[TBL] [Abstract][Full Text] [Related]
18. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA; Wilhelm S; Carter C; Kelley SL
Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
[TBL] [Abstract][Full Text] [Related]
19. Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma.
Panka DJ; Atkins MB; Mier JW
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2371s-2375s. PubMed ID: 16609061
[TBL] [Abstract][Full Text] [Related]
20. Emerging targets for hematological malignancies.
Cilloni D; Frassoni F; Saglio G
Curr Opin Drug Discov Devel; 2010 Sep; 13(5):548-58. PubMed ID: 20812146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
